Oxford University Press

SHERPA: Yellow

People

  1. Drilon
    Drilon
  2. Motzer
    Motzer
  3. Mellinghoff
    Mellinghoff
  4. Shuman
    Shuman
  5. Rosenblum
    Rosenblum
  6. Dunkel
    Dunkel
  7. Karajannis
    Karajannis
  8. Saltz
    Saltz
  9. Souweidane
    Souweidane
  10. O'Reilly
    O'Reilly

Groups

  1. Department of Medicine (1996)
  2. Solid Tumor Oncology Division (1625)
  3. GSK Faculty (766)
  4. Survivorship Research (640)
  5. Population Sciences Research Program (616)
  6. Epidemiology and Biostatistics (466)
  7. Department of Pathology and Laboratory Medicine (416)
  8. Gastrointestinal Oncology Service (387)
  9. Genitourinary Oncology Service (367)
  10. Tow Center for Developmental Oncology (TCDO) (352)
Search Within
Formats
  1. Journal Article (2131)
  2. Meeting Abstract (2072)
  3. Book Section (192)
  4. Review (92)
  5. Editorial (84)
  6. Guidelines (36)
  7. Correspondence (26)
  8. Book Whole (18)
  9. Conference Paper (15)
  10. Research Letter (10)
Groups
  1. Department of Medicine (1996)
  2. Solid Tumor Oncology Division (1625)
  3. GSK Faculty (766)
  4. Survivorship Research (640)
  5. Population Sciences Research Program (616)
  6. Epidemiology and Biostatistics (466)

More Groups

People
  1. Lisa De Angelis (119)
  2. Alexander Drilon (108)
  3. Robert Motzer (96)
  4. Ingo Mellinghoff (93)
  5. Stewart Shuman (88)
  6. Marc Rosenblum (87)

More People

Years
  1. 2025 (129)
  2. 2024 (304)
  3. 2023 (320)
  4. 2022 (331)
  5. 2021 (323)
  6. 2020 (325)

More Years

Publications
  1. Annals of Oncology (1670)
  2. Neuro-Oncology (855)
  3. JNCI: Journal of the National Cancer Institute (492)
  4. Nucleic Acids Research (210)
  5. Clinical Infectious Diseases (140)
  6. American Journal of Clinical Pathology (106)

More Publications

Results (4676)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Activity of afatinib/cetuximab in patients (pts) with EGFR-mutant non-small cell lung cancer (NSCLC) and acquired resistance (AR) to EGFR inhibitors
    Meeting Abstract

    Janjigian, Y. Y.; Smit, E. F.; Horn, L.; Groen, H. J. M.; Camidge, D. R.; Gettinger, S.; Fu, Y.; Denis, L. J.; Miller, V.; Pao, W.
    Annals of Oncology (2012)

    Fulltext@MSK | Save
  • EGFR and P53 expression in androgen receptor (AR)-positive, triple negative breast cancer (TNBC)
    Meeting Abstract

    Gucalp, A.; Gupta, G.; Patil, S.; Wen, Y. H.; Akram, M.; Brogi, E.; Powell, S.; Ho, A.; Hudis, C. A.; Traina, T. A.
    Annals of Oncology (2012)

    Fulltext@MSK | Save
  • Impact of enzalutamide, an androgen receptor signaling inhibitor, on time to first skeletal related event (SRE) and pain in the phase 3 AFFIRM study
    Meeting Abstract

    Fizazi, K.; Scher, H. I.; Saad, F.; Sternberg, C. N.; Miller, K.; Mulders, P.; Chi, K.; Basch, E.; Hirmand, M.; de Bono, J. S.
    Annals of Oncology (2012)

    Fulltext@MSK | Save
  • Detailed comparison of the safety of tivozanib versus sorafenib in patients with advanced/metastatic renal cell carcinoma (mRCC) from a phase 3 trial
    Meeting Abstract

    Eisen, T. Q. G.; Sternberg, C. N.; Tomczak, P.; Harza, M.; Jinga, V.; Esteves, B.; Motzer, R. J.
    Annals of Oncology (2012)

    Fulltext@MSK | Save
  • Comparative assessment of sunitinib-associated adverse events (AES) as potential biomarkers of efficacy in metastatic renal cell carcinoma (mRCC)
    Meeting Abstract

    Donskov, F.; Michaelson, M. D.; Puzanov, I.; Davis, M. P.; Bjarnason, G. A.; Motzer, R. J.; Lin, X.; Cohen, D. P.; Wiltshire, R.; Rini, B. I.
    Annals of Oncology (2012)

    Fulltext@MSK | Save
  • Cabozantinib (XL184) at 40 mg in patients with metastatic castration resistant prostate cancer (mCRPC): Results of a phase 2 non-randomized expansion cohort (NRE)
    Meeting Abstract

    de Bono, J. S.; Smith, M. R.; Rathkopf, D.; Corn, P. G.; Mukherji, D.; Harzstark, A. L.; Sartor, O. A.; Smith, D. C.; Tunariu, N.; Sweeney, C.
    Annals of Oncology (2012)

    Fulltext@MSK | Save
  • The analytical validation of prostate specific mRNA detection in whole blood by reverse transcription-polymerase chain reaction (RT-PCR) as a prognostic biomarker for patients with castration-resistant prostate cancer (CRPC)
    Meeting Abstract

    Danila, D.; Anand, A.; Heller, G.; Wan, M.; Zehnder, M.; Khanin, R.; Schultz, N.; Fleisher, M.; Lilja, H.; Scher, H. I.
    Annals of Oncology (2012)

    Fulltext@MSK | Save
  • Brain metastases (BM) in patients (pts) with soft tissue and bone sarcoma (SARCOMA): A retrospective study of 107 pts
    Meeting Abstract

    Cioffi, A.; Italiano, A.; Maki, R. G.; Keohan, M. L.
    Annals of Oncology (2012)

    Fulltext@MSK | Save
  • Effects of chemotherapy on ipilimumab-mediated increases in absolute lymphocyte count and activation of T cells
    Meeting Abstract

    Chasalow, S. D.; Wolchok, J. D.; Reck, M.; Maier, S.; Shahabi, V.
    Annals of Oncology (2012)

    Fulltext@MSK | Save
  • A phase 2 randomized study of ramucirumab (IMC 1121B; RAM) with or without dacarbazine (DTIC) in patients (pts) with metastatic melanoma (MM) (CP12-0604/NCT00533702)
    Meeting Abstract

    Carvajal, R.; Thompson, J.; Gordon, M.; Lewis, K.; Pavlick, A.; Wolchok, J.; Rojas, P.; Schwartz, J.; Bedikian, A.
    Annals of Oncology (2012)

    Fulltext@MSK | Save